Hoosiers insured through Medicaid will soon gain access to GLP-1 medications for obesity. Mike Braun on Thursday directed the Indiana Family and Social Services Administration, which administers Medicaid benefits to 1.9 million Hoosiers, to participate in a federal initiative to cover GLP-1 medications for obesity. The Centers for Medicare & Medicaid Innovation Center is working with drug makers like Eli Lilly and Novo Nordisk to make GLP-1 medications more affordable — for state Medicaid programs and beneficiaries alike. States that opt into the BALANCE model can access GLP-1 medications at a lower cost. Indiana Medicaid will pay $85.16 of the $245 monthly cost per person, thanks to contributions from the federal government and manufacturer discounts.